Patent ID: 9718766
Date: 2017-08-01
CPC Classifications: A61K,A61P,C07C,C07D,C07K

Claim:
1. A method for treating Parkinson disease in a subject comprising administering transdermally a pharmaceutical composition comprising one or more high penetration pro-drugs selected from Structure Pro-L-Dopa-1, Structure Pro-L-Dopa-2, Structure Pro-L-Dopa-3, Structure Pro-L-Dopa-4, Structure Pro-L-Dopa-5, Structure Pro-dopamine-1, Structure Pro-dopamine-2, Structure Pro-dopamine-3, Structure Pro-dopamine-4, and Structure Pro-dopamine-5: stereoisomers, and pharmaceutically acceptable salts thereof, wherein W is selected from H, substituted and unsubstituted alkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocycloalkyl, substituted and unsubstituted alkyloxy, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted aryl, substituted and unsubstituted heteroaryl, the protonatable amine group, pharmaceutically acceptable substituted and unsubstituted amine groups, Structure W-1, Structure W-2, Structure W-3, Structure W-4, Structure W-5, Structure W-6, Structure W-7, Structure W-8, Structure W-9, Structure W-10, Structure W-11, and Structure W-12: HA is selected from nothing and a pharmaceutically acceptable acid; X is selected from O, S, and NR X X Y Y Y n and m are independently selected from 0, 1, 2, 3, 4, 5, 6, 7, and 8; Rc is selected from nothing, CH R is selected from nothing, CH R each R each R R R and an agent selected from a high penetration prodrug of aspirin, a high penetration prodrug of another nonsteroidal anti-inflammatory drug (NSAID), and any combination thereof; and administering orally an aromatic-L-amino-acid decarboxylase inhibitor selected from carbidopa, benserazide, difluromethyldopa, α-methyldopa, and a pharmaceutical composition thereof; and/or administering a catechol-O-methyl transferase inhibitor selected from entacapone, tolcapone; and a pharmaceutical composition thereof.